Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff ConcernsSeeking Alpha • 07/16/25
Amgen (AMGN) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 07/11/25
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo NordiskThe Motley Fool • 07/02/25
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCERPRNewsWire • 06/30/25
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?Zacks Investment Research • 06/27/25
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose IssuesBenzinga • 06/24/25
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONSPRNewsWire • 06/23/25
Amgen Expands Development Plans For Highly Anticipated Obesity DrugInvestors Business Daily • 06/23/25
AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONSPRNewsWire • 06/18/25
Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptSeeking Alpha • 06/10/25